TY - JOUR
T1 - Workshop 5
T2 - Assessment of efficacy
AU - Busse, William W.
AU - Wilson, Archie F.
AU - Bodenheimer, Saul S.
AU - Fairshter, Ronald D.
AU - Lockey, Richard F.
AU - Nelson, Harold S.
AU - Norman, Philip S.
AU - Reisman, Robert E.
AU - Russell, Patricia H.
AU - Winter, David L.
PY - 1986/9
Y1 - 1986/9
N2 - The efficacy of NBAAD can be assessed by periodic timed evaluation with precise spirometry and daily peak flow determinations and by measuring effect on airway hyperresponsiveness before, during, and after the drug trial. In addition, close monitoring and careful analyses of symptoms and use of concomitant medications are important efficacy parameters. Under certain conditions eosinophils in blood and sputum may provide useful objective criteria of efficacy. Demonstration of improvement in asthma with NBAAD should be based on a collective assessment of airway function, daily symptoms, and use of concomitant medications.
AB - The efficacy of NBAAD can be assessed by periodic timed evaluation with precise spirometry and daily peak flow determinations and by measuring effect on airway hyperresponsiveness before, during, and after the drug trial. In addition, close monitoring and careful analyses of symptoms and use of concomitant medications are important efficacy parameters. Under certain conditions eosinophils in blood and sputum may provide useful objective criteria of efficacy. Demonstration of improvement in asthma with NBAAD should be based on a collective assessment of airway function, daily symptoms, and use of concomitant medications.
UR - http://www.scopus.com/inward/record.url?scp=0022553293&partnerID=8YFLogxK
U2 - 10.1016/0091-6749(86)90099-0
DO - 10.1016/0091-6749(86)90099-0
M3 - Review article
AN - SCOPUS:0022553293
SN - 0091-6749
VL - 78
SP - 525
EP - 528
JO - Journal of Allergy and Clinical Immunology
JF - Journal of Allergy and Clinical Immunology
IS - 3 PART 2
ER -